SAN DIEGO, Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell ...
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).
SAN DIEGO., Mast Therapeutics, Inc. a biopharmaceutical company developing novel clinical-stage therapies for sickle cell disease and heart failure, today reported positive top-line results from a ...
In a recent study published in Nature, researchers used a mouse model to show that mast cells and immunoglobulin E (IgE) are the key orchestrators of antigen-specific avoidance, a behavioral ...
Mast Therapeutics, Inc. (NYSE: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in ...
Each year, more than 400 million urinary tract infections occur in people around the globe. And researchers have long been puzzled by a medical mystery: Some women susceptible to recurrent UTIs ...
Mast Therapeutics Inc. has initiated a new open-label extension study to evaluate repeat dosing of its experimental sickle cell disease (SCD) therapy, vepoloxamer (MST-188), in patients who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results